SERIES B·Nov 15, 2026, 10:12 AM ET·Emerging signal

Nanopath secures $25M to advance a 15-minute vaginitis diagnostic

TL;DR:

  • Nanopath secured $25 million through a Series B round.
  • Nanopath will direct funding toward manufacturing expansion, clinical studies and a larger team.
  • Nanopath is developing a vaginitis test designed for 15-minute results where patients receive care.

Summary

Nanopath secured a $25 million Series B to advance its vaginitis diagnostic. The test is intended to provide results in 15 minutes at the care site. Funding will support manufacturing expansion, clinical studies and hiring, addressing both production capacity and the work needed to evaluate the diagnostic.

Open masslifesciences.com in a new tab ↗
Powered by Moatly Lens

The Bigger Picture

The headline tells you what happened. Discover the facts behind it, the forces at work, the connections that matter, and what comes next.

Why This Matters

Nanopath is looking to change women's healthcare with a new $25 million investment for its 15-minute diagnostic test.

What We Actually Know

  • Reported, not yet confirmedThe funding will be used to grow the team, expand manufacturing, and conduct clinical studies.

How the Pieces Connect

  • InferenceReported, not yet confirmedCurrent diagnostics often require off-site lab processing, so a 15-minute on-site result would significantly speed up treatment decisions.

What This Could Change

  • ScenarioIf clinical studies succeed, this could become a standard tool in primary care clinics, reducing the need for follow-up appointments.

Where the Story Goes Next

  • What is the expected price point for the diagnostic hardware and individual test cartridges?